Tapeworm Drug Shows Promise in Treating Endometriosis in Mice

A drug commonly used to treat tapeworm infections has shown potential as a new treatment for endometriosis, according to a recent study.

Researchers have found that niclosamide, an FDA-approved anti-worm medication, when modified with nanotechnology, significantly reduced inflammation and slowed the progression of endometriosis-like lesions in mice. Endometriosis is a chronic, painful inflammatory disease that affects an estimated 1 in 10 women of reproductive age worldwide, yet currently lacks a cure.

Existing treatments for endometriosis, such as hormonal therapies and surgeries, primarily focus on managing symptoms and removing lesions, but they can come with side effects or may not prevent lesion regrowth. The new research, published in Advanced Healthcare Material, explored a different approach by targeting the underlying inflammation and lesion spread.

The study identified a specific group of rogue immune cells associated with endometrial lesions that drive pain and inflammation. These cells possess a unique marker, a folate receptor, making them a potential target for drug delivery.

To adapt niclosamide for this purpose, scientists combined it with nanotech. The drug was attached to a molecule called a dendrimer, essentially acting as a vehicle, with a folate receptor guiding it to the specific target cells. This nanotech 'armor' ensures the drug remains inactive in general circulation and is released primarily within the diseased cells.

"The drug is attached in such a way that when it is in systemic circulation, nothing happens until it goes inside the diseased cells," Anjali Sharma, a nanomedicine specialist at the University of Michigan involved in the research, explained to Live Science. Once inside the target cells, the drug is slowly released over two weeks.

In the mouse models, a single injection of the modified niclosamide directly targeted the affected tissue, leading to a marked reduction in pain and a significant slowdown, or even complete halt, in the growth of new lesions. This suggests a potential for a more targeted and effective treatment compared to current options.

However, researchers acknowledge that mice do not menstruate or naturally develop endometriosis, highlighting the need for further investigation. Despite these limitations, the study's findings have generated considerable interest, with hundreds of inquiries received from individuals eager to participate in future trials.

The next steps for the research involve testing the medication in larger animal models and, if successful, proceeding to human clinical trials. Experts in the field see promise in repurposing existing, tested drugs like niclosamide for conditions such as endometriosis, potentially offering a new avenue for millions of women suffering from this debilitating disease.